Navigation Links
Sinovac Announces Adjournment of Annual General Meeting
Date:3/25/2008

BEIJING, March 25 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that its Annual General Meeting originally scheduled for March 25, 2008 has been adjourned to April 8, 2008.

At the March 25, 2008 Annual General Meeting, the required quorum of a majority of the outstanding shares was not present. In accordance with Antigua law, the meeting is adjourned to April 8, 2008 (the same day two weeks after March 25), 9 a.m. Beijing time at Sinovac's headquarters located at No. 39, Shangdi Xi Rd., Haidian District, Beijing, PRC (the same time and place as the originally scheduled meeting). Under Antigua law and in compliance with American Stock Exchange requirements, if a quorum is not present within thirty minutes of the appointed time for holding the adjourned meeting, the shareholders then present representing at least one-third of the total outstanding shares will constitute a quorum.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, Japanese encephalitis and SARS. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington/Janine McCargo

The Ruth Group

Tel: +1-646-536-7017/7033

Email: scarrington@theruthgroup.com

jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
2. Sinovac Closes $9.75 Million Private Placement
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Sinovac Requests Extension for Annual Shareholders Meeting
5. Sinovac Announces Postponement of Annual General Meeting
6. CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve
7. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)
8. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
9. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
10. Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA
11. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Dublin - Research and Markets has ... Market-By Type, By Application, By End User, By Region, By Country: ... ... Market is forecasted to grow at a CAGR of 11.33% during ... crop protection market is driven by the surging demand for less ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... Dr. Daniel Spyker, PhD, MD former Acting Deputy Director in the FDA CDRH ... Drug Evaluation Staff has joined the company as an Expert Consultant. , In ...
(Date:2/22/2017)... and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 /PRNewswire/ ... today announced its financial results for the fourth ... "Our annual 2016 financial results reflect continued growth ... exceeded $700 million," said Martine Rothblatt, Ph.D., United ... results strengthen our ability to develop and advance ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS 2017, ... health applications, announced a partnership with Redox, a leader in cloud-based healthcare integration ... clinical systems while keeping data secure in the cloud. , The digital health ...
Breaking Biology Technology:
(Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
Breaking Biology News(10 mins):